Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Myasthenia gravis (MG) should be classified according to antibody status (acetylcholine, MuSK, LRP4, titin), thymus (hyperplasia, neoplasia, atrophy), age at debut (< or >50 years), symptom ...

Real estate agent Kirsten Jordan breaks down the latest trends in the housing market, near-record home sale cancellations in April and her outlook on mortgage rates. Myasthenia gravis is a rare, ...

Myasthenia Gravis Foundation of America (MGFA™), the largest, leading patient advocacy organization in the United States ...

ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) ...

The approval marks the second international approval for rozanolixizumab (Rystiggo; UCB Pharma) for generalized myasthenia gravis (gMG), behind the February EU approval of 2 self-administration ...

Myasthenia gravis patients show higher rates of dysarthria, dysphonia, dysphagia, and aspiration pneumonia compared to non-affected individuals. Despite high disorder rates, most myasthenia gravis ...

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major ...

GlycoEra’s lead candidate targets IgG4 autoantibodies, potentially addressing autoimmune diseases such as muscle-specific ...

Imaavy is the first FcRn blocker approved for anti-AChR and anti-MuSK antibody positive patients with generalized myasthenia gravis. The Food and Drug Administration (FDA) has approved Imaavy ...

The US FDA has approved Johnson & Johnson's drug to treat patients aged 12 years and older with an immune-mediated disorder ...